Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01119833 · ClinicalTrials.gov registry record · Phase 2
Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
A Phase 2 study, sponsored by GlycoMimetics Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT01119833: Completed Phase 2 study, sponsored by GlycoMimetics Incorporated.
NCT01119833 is a Phase 2 study that has completed, run by GlycoMimetics Incorporated. The registered enrollment target is 81 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01119833, a Phase 2 study, has completed, sponsored by GlycoMimetics Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
GMI-1070 is a new drug that may reduce the stickiness of cells in the blood. The purpose of this study is to evaluate whether GMI-1070 can reduce the time it takes for pain to go away in patients with vaso-occlusive crisis (also known as a sickle cell pain crisis). The study will also collect information on the safety of GMI-1070, how much of the drug is in the blood and urine, and if there are any other effects when used in patients who are in the hospital for a sickle cell pain crisis.
Primary Outcome
Including pain score, feeling ready to leave the hospital, and actual time of leaving the hospital
Interventions
- DRUG Placebo
- DRUG GMI-1070
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
What the finished NCT01119833 record still lists
NCT01119833 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01119833 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01119833 about?
NCT01119833 is a clinical study titled "Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis". GMI-1070 is a new drug that may reduce the stickiness of cells in the blood. The purpose of this study is to evaluate whether GMI-1070 can reduce the time it takes for pain to go away in patients with vaso-occlusive crisis (also known as a sickle cell pain crisis). The study will also collect inform...
What is the current status of trial NCT01119833?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2010-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01119833?
The interventions under investigation include: Placebo (DRUG), GMI-1070 (DRUG).
Who is sponsoring clinical trial NCT01119833?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01119833's enrollment target sits among peer trials
81 834th of 2000 higher than 1,159 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia